S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
US economy grew solid 3.2% in fourth quarter, a slight downgrade from government's initial estimate
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
US economy grew solid 3.2% in fourth quarter, a slight downgrade from government's initial estimate
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
US economy grew solid 3.2% in fourth quarter, a slight downgrade from government's initial estimate
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
US economy grew solid 3.2% in fourth quarter, a slight downgrade from government's initial estimate
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots

Sintx Technologies (SINT) Competitors

$0.14
-0.01 (-6.79%)
(As of 02/28/2024 ET)

SINT vs. NVIV, BJDX, MOTS, RSLS, NMRD, INVO, DYNT, IONM, TNON, and QNRX

Should you be buying Sintx Technologies stock or one of its competitors? The main competitors of Sintx Technologies include InVivo Therapeutics (NVIV), Bluejay Diagnostics (BJDX), Motus GI (MOTS), ReShape Lifesciences (RSLS), Nemaura Medical (NMRD), INVO Bioscience (INVO), Dynatronics (DYNT), Assure (IONM), Tenon Medical (TNON), and Quoin Pharmaceuticals (QNRX). These companies are all part of the "surgical & medical instruments" industry.

Sintx Technologies vs.

Sintx Technologies (NASDAQ:SINT) and InVivo Therapeutics (NASDAQ:NVIV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking.

InVivo Therapeutics has lower revenue, but higher earnings than Sintx Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sintx Technologies$1.56M0.47-$12.04MN/AN/A
InVivo TherapeuticsN/AN/A-$10.49MN/AN/A

InVivo Therapeutics has a net margin of 0.00% compared to Sintx Technologies' net margin of -397.27%. InVivo Therapeutics' return on equity of -75.04% beat Sintx Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Sintx Technologies-397.27% -85.77% -54.20%
InVivo Therapeutics N/A -75.04%-65.01%

Sintx Technologies has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, InVivo Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.

2.7% of Sintx Technologies shares are owned by institutional investors. Comparatively, 13.8% of InVivo Therapeutics shares are owned by institutional investors. 0.8% of Sintx Technologies shares are owned by insiders. Comparatively, 2.5% of InVivo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sintx Technologies
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
InVivo Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

InVivo Therapeutics received 194 more outperform votes than Sintx Technologies when rated by MarketBeat users. However, 61.02% of users gave Sintx Technologies an outperform vote while only 56.65% of users gave InVivo Therapeutics an outperform vote.

CompanyUnderperformOutperform
Sintx TechnologiesOutperform Votes
36
61.02%
Underperform Votes
23
38.98%
InVivo TherapeuticsOutperform Votes
230
56.65%
Underperform Votes
176
43.35%

In the previous week, Sintx Technologies had 3 more articles in the media than InVivo Therapeutics. MarketBeat recorded 4 mentions for Sintx Technologies and 1 mentions for InVivo Therapeutics. Sintx Technologies' average media sentiment score of 0.84 beat InVivo Therapeutics' score of 0.00 indicating that Sintx Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sintx Technologies
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
InVivo Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Sintx Technologies and InVivo Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.


Get Sintx Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for SINT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SINT vs. The Competition

MetricSintx TechnologiesSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$730,000.00$3.73B$5.01B$7.50B
Dividend YieldN/A2.03%2.87%3.87%
P/E RatioN/A11.66203.1414.88
Price / Sales0.4727.042,984.0970.55
Price / CashN/A25.6294.3454.60
Price / Book0.014.004.454.63
Net Income-$12.04M$10.30M$112.60M$211.02M
7 Day Performance-2.00%2.14%4.72%2.28%
1 Month Performance-49.63%28.07%9.87%3.39%
1 Year Performance-95.10%1.27%12.47%7.45%

Sintx Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVIV
InVivo Therapeutics
0 of 5 stars
N/AN/A-84.0%$997,000.00N/A0.006Analyst Report
Gap Down
BJDX
Bluejay Diagnostics
2.5802 of 5 stars
$0.81
+2.5%
N/A-94.3%$1.00M$250,000.00-0.0816Short Interest ↓
Gap Down
MOTS
Motus GI
2.4711 of 5 stars
$0.65
+1.6%
$28.88
+4,326.6%
-95.1%$450,000.00$590,000.00-0.0243Short Interest ↑
High Trading Volume
RSLS
ReShape Lifesciences
0.7533 of 5 stars
$0.17
-5.7%
$8.00
+4,728.0%
-96.2%$2.18M$11.24M0.0040High Trading Volume
NMRD
Nemaura Medical
2.2271 of 5 stars
$0.08
-11.6%
$4.25
+5,492.1%
-91.4%$2.20M$80,000.00-0.1936
INVO
INVO Bioscience
0 of 5 stars
$0.94
+6.8%
N/A-91.0%$2.32M$820,000.00-0.0815Short Interest ↓
DYNT
Dynatronics
1.8616 of 5 stars
$0.49
flat
$3.80
+683.5%
-73.2%$2.37M$40.61M-0.35154Analyst Report
Short Interest ↓
Gap Up
IONM
Assure
1.9423 of 5 stars
$0.35
+12.8%
$8.00
+2,166.3%
-94.7%$2.37M$10.85M0.00127Short Interest ↑
Positive News
Gap Down
High Trading Volume
TNON
Tenon Medical
1.9522 of 5 stars
$1.08
-11.5%
$6.00
+455.5%
-47.5%$2.67M$2.40M-0.0722Gap Up
QNRX
Quoin Pharmaceuticals
0.2761 of 5 stars
$2.83
+2.5%
N/A-57.4%$2.80MN/A-0.224News Coverage
Gap Up

Related Companies and Tools

This page (NASDAQ:SINT) was last updated on 2/29/2024 by MarketBeat.com Staff